CartiHeal (Israel) Announces FDA IDE Approval of its Agili-C Implant for the Treatment of Joint Surface Lesions

Israeli company CartiHeal (2009), developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application.…











